What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially announce and provide access to Abbott Laboratories' financial results for the second quarter of 2019. It furnishes the press release that contains these results.

What are non-GAAP financial measures, and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from the standard GAAP (Generally Accepted Accounting Principles) calculations. Abbott uses them to provide investors with a clearer view of ongoing business performance by excluding unusual or unpredictable items like acquisition costs, restructuring expenses, and the impact of tax reform. Management believes these measures help in assessing the core operational results.

Where can I find the actual financial results for the second quarter of 2019?

The actual financial results are detailed in the press release dated July 17, 2019, which is furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to this press release for comprehensive financial data and performance details.

Are the non-GAAP measures presented by Abbott reliable for investors?

Abbott's management believes its non-GAAP measures provide useful information for investors to better evaluate ongoing business performance. However, the company cautions investors to consider these non-GAAP measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP. Investors should analyze both to get a complete understanding.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on July 17, 2019, to report its second quarter 2019 financial results. The filing primarily serves to furnish the press release detailing these results. Investors should note that Abbott uses both GAAP and non-GAAP financial measures. The company emphasizes that its non-GAAP measures, which exclude specified items like acquisition and restructuring costs, tax reform impacts, and debt extinguishment, are used by management to assess ongoing business performance and provide greater visibility into operational results. While the 8-K itself does not contain the detailed financial figures, it directs investors to the furnished press release (Exhibit 99.1) for a comprehensive understanding of the second quarter performance. Investors are encouraged to review these non-GAAP measures alongside GAAP figures to gain a fuller picture of Abbott's financial condition, as management believes these provide valuable insights into the company's operational health and performance trends, excluding certain unusual or unpredictable factors.

Key Highlights

1Abbott Laboratories announced its second quarter 2019 financial results on July 17, 2019, via an 8-K filing.
2The 8-K filing primarily furnished a press release (Exhibit 99.1) containing the detailed financial results.
3Abbott utilizes non-GAAP financial measures in its reporting, excluding items such as acquisition, restructuring, and tax reform-related expenses.
4The company states that these non-GAAP measures offer greater visibility into ongoing business performance and are used internally by management.
5Investors are advised to consider these non-GAAP measures in conjunction with, and not as a substitute for, GAAP financial measures.
6The filing was signed by Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer.

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 17, 2019)

Summary

Key Highlights

Frequently Asked Questions